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A B S T R A C T
The new zoonotic coronavirus (SARS-CoV-2) responsible for coronavirus disease (COVID-19) is a new strain of
coronavirus not previously seen in humans and which appears to come from bat species. It originated in Wuhan,
Hubei Province, China, and spread rapidly throughout the world, causing over 5,569,679 global cases and
351,866 deaths in almost every country in the world, including Europe, particularly Italy. In general, based on
existing data published to date, 80.9% of patients infected with the virus develop mild infection; 13.8% severe
pneumonia; 4.7% respiratory failure, septic shock or multi-organ failure; 3% of these cases are fatal. Critical
patients have been shown to develop acute respiratory distress syndrome (ARDS) and hospitalization in intensive
care units. The average age of patients admitted to hospital is 57–79 years, with one third half with an un-
derlying disease. Asymptomatic infections have also been described, but their frequency is not known. SARS-
CoV-2 transmission is mainly airborne from one person to another via droplets. The data available so far seem to
indicate that SARS-CoV-2 is capable of producing an excessive immune reaction in the host. The virus attacks
type II pneumocytes in the lower bronchi through the binding of the Spike protein (S protein) to viral receptors,
of which the angiotensin 2 conversion enzyme (ACE2) receptor is the most important. ACE2 receptor is widely
expressed in numerous tissues, including the oropharynx and conjunctiva, but mostly distributed in ciliated
bronchial epithelial cells and type II pneumocytes in the lower bronchi. The arrival of SARS-CoV-2 in the lungs
causes severe primary interstitial viral pneumonia that can lead to the “cytokine storm syndrome”, a deadly
uncontrolled systemic inflammatory response triggered by the activation of interleukin 6 (IL-6), whose effect is
extensive lung tissue damage and disseminated intravascular coagulation (DIC), that are life-threatening for
patients with COVID-19. In the absence of a therapy of proven efficacy, current management consists of off-label
or compassionate use therapies based on antivirals, antiparasitic agents in both oral and parenteral formulation,
anti-inflammatory drugs, oxygen therapy and heparin support and convalescent plasma. Like most respiratory
viruses can function and replicate at low temperatures (i.e. 34–35 °C) and assuming viral thermolability of SARS-
CoV-2, local instillation or aerosol of antiviral (i.e. remdesivir) in humid heat vaporization (40°–41 °C) in the first
phase of infection (phenotype I, before admission), both in asymptomatic but nasopharyngeal swab positive
patients, together with antiseptic-antiviral oral gargles and povidone-iodine eye drops for conjunctiva (0,8–5%
conjunctival congestion), would attack the virus directly through the receptors to which it binds, significantly
decreasing viral replication, risk of evolution to phenotypes IV and V, reducing hospitalization and therefore
death.
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Introduction and background
[In nulla parte naturae maiora esse miracula quam in acquis calidis.
Plinius Maior (23–79 p.C.n), Naturalis Historia]
The nose and throat setting
A normal breathing means 6 lt air/minute. Air is climatized in nose
cavity, and independently from external temperature is sent to lungs via
trachea at 31°–34 °C and 90–95% humidity. The bronchial-alveolar
temperature is 37°–38 °C. Air is cleaned from about 85% from parti-
cles> 4.5 µm by mucous-ciliary clearance that transports germs from
the nose through pharynx to the stomach for gastric destruction. The
nasopharyngeal cavity is naturally exposed to the penetration of pa-
thogenic bacteria that forcefully adhere to the walls and creep into the
lymphatic folds maintaining a persistent bacterial load [1]. The He-
mophilus Influenzae (HI) and the Streptococcus Pneumoniae (SP), which
together with the Moraxella catarrhalis are considered the ‘infernal trio’;
the most frequent pathogens of the URDT (upper respiratory digestive
tract) are instead present in healthy individuals only in 6% of the nasal
samples and in 27% of the pharyngeal samples with a clear prevalence
HI (5%) compared to SP (0.5%). In healthy subjects the anaerobic nasal
culture is always characterized by the presence of Propionibacterium
acnes in 74.5% and Peptococcus magnus in 3.5%. Viruses cause 85% to
95% of throat infections in adults and children younger than 5 years of
age; for those aged 5 to 15 years, viruses cause about 70%/ of throat
infections, with the other 30% due to bacterial infections, mostly group
A β-hemolytic streptococcus (GABHS) [2]. NK cells are there largely
active.
The processes that take place in the lungs are basically isothermal.
The air in the lungs is saturated with water vapor at the internal body
temperature. The water vapor in a saturated mixture is characterized by
a partial pressure which mainly depends only on the temperature.
Under these conditions, the water vapor does not behave like a com-
pressible gas and its partial pressure PH2O depends only on temperature:
47 mmHg at 37 °C. The heat transfer between a heated stationary body
and a moving fluid that invests it, depends on the speed, thermal
conductivity and temperature of the fluid [3,4].
An apparent bias could be overcome separating the air volume in-
troduced with nasal inspiration (which reaches the trachea and bronchi
at an air-conditioned temperature of 34° C, whatever the outside tem-
perature) and the volume introduced directly by mouth, which without
nasal humidification and filtration, cools the oropharynx and the ring of
Waldeyer and reaches service temperatures only in the trachea. In case
of SARS-CoV-2 contagion, the cooling and drying of the pharynx can
explain the onset with pharyngodynia; mucosal membrane infection of
nose and sinuses explain rhinorrhea with anosmia and dysgeusia for
viral neurotropism to olfactory and taste nerve receptors (a possible
way to reach the brain), and conjunctivitis for mucosal continuity, as
well as for direct insemination (droplets): the air temperature in-
troduced via the nasal route is similar to the limbo-conjunctival tem-
perature (Fig. 1a–b).
The eye setting
The temperature of the exposed corneal surface is around 34 °C
(32.8 to 35,4°C) [5], the limbus being 0,45 °C warmer than the apex.
Ocular surface cooled during sustained eye opening and rate of the
cooling was greater in the dry eye patient (mostly older people and
video terminal operator) [6], while it increases to 36°–37 °C at the
conjunctival fornix . In the logical context of this paper, this would
justify the related conjunctivitis SARS-CoV-2/19. Indeed, phar-
yngodinia and low-temperature related conjunctivitis is a common
finding in respiratory virus infections. A report in The Lancet, raised
concern that ocular surfaces may be a potential target for human- SARS-
CoV-2 invasion via droplets, as published by Sun and Coll [7a,b] in two
consecutive papers collected in two different period: in Huazhong
province from the end of December 2019 till February 7th 2020, and in
Hubei province in the second week of February 2020, that had similar
results. Twelve (32%) patients in the first series had conjunctivitis with
signs that included conjunctival hyperemia, chemosis, epiphora, and
increased secretions. Of those patients, 11 (92%) tested positive for
CoV-19 by nasopharyngeal swab. In one patient, epiphora was the first
symptom of COVID-19. Twenty-eight (74%) of the 38 patients in the
second one was positive for CoV-19 by nasopharyngeal swabs, of whom
only two (5%) patients had a positive conjunctival specimen, whilst
Guan and Coll [8] on NEJM, documented ‘’conjunctival congestion’’ in
9 of 1.099 patients (0,8%) across China, with laboratory confirmed
CoV-19. So, a largely approximated valuation would point out about
0,8–5% locally positive patients of those affected by conjunctivitis in
evolved stages [9] (the virus possibly vanished in the meantime or by
therapy). Still remaining unknown the percentage in phenotype I and in
asymptomatic pre-clinical (the majority!) patients. Aged patients have
higher rate of dry eye that could justify or amplify the virus con-
junctival access to the body, reaching the nose via the lacrimal ductus.
Environmental control should therefore take into consideration topical
humidification preferably with a cross-linked hyaluronate drops and a
hot vaporization (suffumigation, water hot-humid vaporization (WHV)
[10]) involving also the upper airways in mucosal continuity with the
conjunctiva (Fig. 2). It must be humid: an air dryer evaporates the tear
film, drastically reduces lactoferrin, mucin trap-door effectiveness and
macrophages activity; in addition to the peptidoglycan N-acetylmur-
amoyl hydrolase (i.e. Fleming's Lysozyme) whose catalysis rate is
maximum at pH5.
The Hypothesis/Theory
Most respiratory virus may work and replicate at lower tempera-
tures (34°–35 °C) than the optimal range for epithelial tracheal-bron-
chial cells (37°–38 °C) [10], either for mucin layer fluidity: exposed to
lower temperatures may less react to fight infections. This also causes
vasoconstriction reducing blood flow and mucin production. Increasing
the air temperature, therefore keeping the upper tract and trachea-
bronchial temperature higher, may reduce the replication and diffusion
of the respiratory virus. Older people have a weak and altered ther-
moregulatory response while children, that quickly develop a high body
temperature that may halt viral replication, and more balanced immune
response, /may have a better chance of fighting infections. SARS-CoV-2
binding the Toll Like Receptor (TLR) causes the release of pro-IL-1β
which is cleaved by caspase-1, followed by inflammasome activation
and production of active mature IL-1βwhich is a mediator of lung in-
flammation, fever and fibrosis [11], cardiovascular implications
[12,13] for increased troponin T (TnT), C-reactive protein and terminal
fragment of type B natriuretic pro-peptide (NT-proBNP), microvascular
endothelial aggression and intestinal-pulmonary cross-talk, with link to
colangiocyte ACE2 receptor, interfering with intestinal microbiota [14]
requiring pro-biotic adjuvant therapy. This infectious disease mostly
affects men, since immune genes are more expressed on the X chro-
mosome [11]. The two coronaviruses that preceded CoV-19 causing
respectively the SARS (Severe Acute Respiratory Syndrome) pandemic
of 2003 [15] and the MERS (Middle East Respiratory Syndrome) epi-
demic of 2012 [16], emerged during the summer and spring-summer
season, thus not respecting the principle that “respiratory viruses can
only function (and replicate) at lower temperatures (i.e. 34–35 °C)”, as
stated [10]. The MERS, moreover, is still ongoing in endemic form since
2012, therefore disrespectful of the summer-winter binomial. These
concepts, are perhaps explainable that both viruses have made the so-
called species jump (Spillover), thus modifying the phenotypic and
genotypic characteristics of both virus. SARS-CoV-2 probably behaves
in the same way. Therefore, it cannot be accurately stated that this is
thermolabile. The biological characteristics of the latter coronavirus are
not yet known; SARS-CoV-2 also made the spillover, but passing
C. Contini, et al. Medical Hypotheses 144 (2020) 109876
2
directly from the bat to the man maybe without an intermediate host
[17]. SARS-CoV-2, as the two recent zoonotic coronavirus, are envel-
oped viruses with round and sometimes pleiomorphic virions of ap-
proximately 80 to 120 nm in diameter. Coronaviruses contain positive-
strand RNA, with the largest RNA genome (approximately 30 kb) re-
ported to date. The genome RNA is complexed with the basic nucleo-
capsid (N) protein to form a helical capsid found within the viral
membrane. The membranes of all coronaviruses contain at least three
viral proteins, of which the most important is the spike (S), the type I
glycoprotein that forms the peplomers on the virion surface, giving the
virus its corona- or crown-like morphology in the electron microscope.
The virus coating consists of a membrane that the virus “inherits” from
the host cell after infecting it. As all viruses, SARS-CoV-2 needs an
animal cell to survive and spread off. Out of this host, virus loses the
ability to survive and infect. Degradation time depends on temperature,
humidity and behavior and belongs to the capsid. For this reason, the
foamy detergents are active for a contact of at least 20 ', the heat de-
grades the membrane lipids, as it happens for alcohol 65%, chloride in
water 1/5 that directly destroys the protein, as for H2O2 at maximal
concentration. It may remain stable in cold outside behavior or in the
air conditioner for more than 3 h and on surfaces for days [18], needing
also humidity and obscurity, being destroyed by UV, hot, dried and
illuminated environments. Up to now is unknown if SARS-CoV-2 in-
duces viremia, as happens in Feline coronavirus [19] that also cause
virus systemic spread, including inflammation of the abdominal and
thoracic cavities and occasionally, other organs including brain [20]
with confusion and epileptic crisis till neurological reliquate needing
rehabilitation, as experienced by many survivors. Anyway, even in the
absence of precise data on viremia, we can with reasonable certainty
state that SARS-CoV-2 runs down to the lung. The virus binds to the
type II pneumocytes from lower bronchi via Spike protein (S-protein)
[17] binding to virus receptors, of which the angiotensin conversion
enzyme 2 (ACE2) receptor is the most important [21]. In the respiratory
tract, ACE2 receptor is widely expressed on type II pneumocytes of the
alveoli, trachea, bronchi, bronchial submucous membrane serous
glands [22], and alveolar monocytes and macrophages. The arrival of
SARS-CoV-2 to the lungs causes primary severe viral interstitial pneu-
monia which in about 10% of cases can degenerate into acute re-
spiratory distress syndrome (ARDS) characterized by a cytochemical
storm triggered by the activation of interleukin 6 (IL-6) [11]: the Cy-
tokine Storm Syndrome (CSS). Blocking the initial binding of the virus to
the ACE2 receptor via the S protein could be one potential treatment
approach avenue. In this context, most efforts are aimed at finding
pharmacological molecules to inhibit this link. Monoclonal antibodies
that target vulnerable sites on viral surface proteins are an emerging
approach for treating some rheumatological disease including arthritis.
In a study by Wang et al. [23], a human antibody known as 47D11,
targeting on communal epitope, was announced to bind to SARS-CoV-
2 and SARS-CoV, and to potently inhibit the virus infection of Vero
cells.
Tissue-resident alveolar macrophages (AMs) are inhabitant of lungs
and are responsible for direct clearance of viruses. A new group of al-
veolar macrophages, dubbed NAMs (nerve and airway associated
macrophages) embryonically derived and self-renewing requiring
colony stimulating factor 1, that proliferated robustly following infec-
tion in the wild-type mice, where recently identified in lung mice [24].
NAMS help regulate and suppress excessive production of cytokines and
immune cell infiltration into tissues. To increase their function or in-
duce their proliferation should be a target for future studies.
Evaluation of the hypothesis/idea
In the absence of a proven effective therapy, current management
consists of supportive care, including invasive and noninvasive oxygen
support and treatment with antibiotics and heparin. In addition, many
patients have received off-label or compassionate-use therapies, in-
cluding antiretrovirals, antiparasitic agents, anti-inflammatory com-
pounds, and convalescent plasma [25–28] always in both oral and
parenteral formulation.
Aim is to find new opportunity to treat SARS-CoV-2 infection both
in early preclinical and in clinical phenotypes using warm humid va-
porization (VHM) and oral pharmacological therapies, always looking
to surrounding symptoms for holistic clinical interpretation. Pre-
Fig. 1. a) The nasal/sinuses air conditioning. b) The oro-pharynx and trachea. Courtesy B.Y. Ghorayeb, www.ghorayeb.net.
Fig. 2. Conjunctival mucosal continuity through lacrimal sac and nasal-la-
chrymal ductus to inferior meatus. Courtesy Minerva Medica, Torino, 1974.
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infection week and the 2 first weeks may be an important window for
any management, according to Paglia phenotypes classification [29]
(Box 1).
Preventive implications: Belcaro et al. [10], postulate that humid
warm air inhalation by aerosol, vaporisation, nebulization (40°- 41 °C)
in the early phases may stop viral replication within hours and may
prevent viral contamination, quickly killing respiratory viruses, as also
suggested with weak evidence by House et al. [30] for bronchiolitis, in
a metanalysis on JAMA Paediatrics. In subsequent cases, the use of
warmer humid air (40–41 °C) in ventilation systems and artificial re-
spirators (WHV) can inactivate viruses or stop their replication in the
respiratory tract helping the recovery process. In fact, the correlation
between lower air/environment temperatures and infections, such as
acute viral infections, is one of the pillars of 'common' hygiene and
medicine, since viruses die when exposed to warmer air [10].
Therefore, a hairdryer may be effective in reducing the virus pa-
thogenicity and inhibiting its activity also on physical surfaces (han-
dles, computer keyboards, car steering wheel, elevator keys, furnishings
or common use on desk, bedside table, etc.) without the need for che-
micals that may cause other problems.
Alcoholic solution for oral gargles, practiced for perceived preven-
tion of viral infection and chemotherapeutic agents, including mouth
rinses, could have role as adjuncts to daily home care, preventing and
controlling supragingival plaque, gingivitis and oral malodor, as
Listerine® that offers a anecdotical protection helping to defend the
oropharynx and the Waldeyer ring, before the tracheal-bronchial in-
vasion, acting against the oral biofilm which contains many microbial
inhabitants including bacteria, viruses and fungi [31], whilst Chlor-
hexidine is ineffective.
Povidone –iodine (Pi: tested on adeno-, mumps, rota-, polio-(types 1
and 3), coxsackie-, rhino-, herpes simplex, rubella, measles, influenza
and human immunodeficiency viruses) instead had a wider virocidal
spectrum, covering both enveloped and nonenveloped viruses, Pi eye
drops are also commercially available in different concentration, and
routinely used before eye surgery [32].
Currently no label specific therapies are available for Covid-19, al-
though many important studies are underway to identify active anti-
viral drugs. Of these, two in particular are in evidence.
- Remdesivir® (RDV). Is a prodrug of a nucleotide analogue that is
intracellularly metabolized to an analogue of adenosine tripho-
sphate that inhibits viral RNA polymerases. RVD has broad- spec-
trum activity against members of several virus families, including
filoviruses (e.g., Ebola) and coronaviruses (e.g., SARS-CoV and
Middle East respiratory syndrome coronavirus [MERS-CoV] and has
shown prophylactic and therapeutic efficacy in nonclinical models
of these coronaviruses.
In vitro testing has also shown that RDV has activity against SARS-
CoV-2. RDV appears to have a favorable clinical safety profile, as re-
ported on the basis of experience in approximately 500 persons, in-
cluding healthy volunteers and patients treated for acute Ebola virus
infection, and supported by our data (on file and shared with the World
Health Organization [WHO]).
- Tocilizumab®. IL-6R blocker protease inhibitors immunosuppressor
humanized monoclonal antibody: suppression of pro-inflammatory
IL-1 family and IL-6 have been shown to have a therapeutic effect in
many inflammatory diseases, including viral infections [11], to
contrast or possibly avoid the CSS. Accumulating evidence suggests
that SARS-COV-2 causes an inflammatory response in the lower
airway and leads to lung injury. Collectively, virus particles invade
the respiratory mucosa first and infect other cells, triggering a
powerful immune response with production of a cytokine storm, i.e.
a deadly uncontrolled systemic inflammatory response in the body
resulting from the release of large amounts of pro-inflammatory
cytokines (IFN-α, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-33, TNF-α,
TGFβ, etc.) and chemokines (CCL2, CCL3, CCL5, CXCL8, CXCL9,
CXCL10, etc.) from immune-effector cells in SARS-CoV-2 infection,
which may be associated with the critical condition of COVID-19
patients [33]. Besides these, other interesting active antiviral com-
pound under evaluation are noticed; some are included in Box 2. In
this setting, is already known that other Authors have also tested the
inhalation of α-interferon by aerosol (5 million U at a time for adults
in sterile water by injection, twice daily) with weak recommenda-
tion [37]. Even tough suggested for reinforcing action on innate
immune system, there are not yet confirmative results on BCG
vaccination. The transplantation of ACE2-mesenchymal stem cells is
still ongoing [38]. Anticoagulants (lmw Heparin) and Antibiotics
(mainly Azithromycin) as supportive therapy are widely used. A
wide range of competitors have a vaccine in the pipeline, with a
large fundraising (even by B&M Gates Foundation), although vac-
cines seem less successful in older people, because aged immune
system do not respond as well to immunization. To treat those in-
fections more infectious and harmful for the elderly, called as geo-
philic and gerolavic infections, Zhakoronkov [39] on Aging, suggests
Rapamycin, Nicotinamide riboside, Metformin, as geroprotectors
with known safety profile, for precautionary measure. A tentative to
empower the innate immunity with Pentraxin 3 (PTX-n3: a humoral
pattern recognition molecule, protein active against other Cor-
onaviruses), for control of Complement activation [40] to also be
used as prognostic for death [41,42] in the CSS, is just tested in an
observational protocol at the Spallanzani (COVID Hospital) in
Rome; anecdoctical of faster improvement in phenotype III-IV using
plasma of recovered positive patients have been reported by Mantua
and Pavia Hospitals. Lastly, a trial with Ruxolitinib® selective in-
hibitor of Janus associate Kinase (JAK1-2) is approved in Italy by
AIFA (Italian Drug Agency), for compassionate use in selected se-
vere patients (phenotypes IV – V). Our suggestion is to test re-
mdesivir® (RDV) in the proposed set. Among antiretrovirals, RDV a
novel anti-viral drug developed by Gilead Sciences, is a prodrug of a
nucleotide analogue that is intracellularly metabolized to an ana-
logue of adenosine triphosphate that inhibits viral RNA poly-
merases) [43]. Remdesivir® has broad-spectrum activity against
members of several virus families, including filoviruses (e.g., Ebola
and Marburg virus infection) and coronaviruses (e.g., SARS-CoV and
MERS-CoV] and has shown prophylactic and therapeutic efficacy in
nonclinical models of these coronaviruses.
This drug has shown in vitro and in animals a high capacity to block
infection and viral replication with attainable concentrations in human
plasma. RDV has been demonstrated to improve pulmonary function
and reduce lung viral loads in mice infected with MERS-CoV. It seems
that by virological and functional analogy, RDV is one of the few an-
tiviral drugs with proven efficacy against SARS-CoV-2. Currently, RDV
is being tested in Italy in patients suffering from COVID-19 pneumonia
in severe or moderate form that do not require mechanical ventilation.
If hot nebulization of RDV (Fig. 3), developed to be used in-
travenously, is administered via aerosol as proposed, SARS-CoV-2
should be sought and monitored at 24 h intervals by RT-PCT (naso-
pharyngeal swab or aspirated in endotracheal tube) in patients in se-
vere clinical conditions and in intensive care units (ICUs) immediately
after aerosol of this antiviral drug, to clarify the local activity other than
systemic evolution of the disease. The nucleotide analog, once phos-
phorylated, works as antimetabolite, being incorporated into growing
DNA strands, acting as chain terminator and stops viral DNA. But being
not specific to viral DNA, they also affect mithocondrial DNA, gen-
erating side effects such as bone marrow suppression. Moreover, it is
not known if the RDV hot nebulization could alter the effectiveness of
the drug administered by this route. There are approved clinical trial all
over the world, trying to demonstrate the in vivo intravenous efficacy of
this drug known for its in vitro activity [43]. Two phase III trials in
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hospitalized adult with mild/moderate (NCT04252664) or severe
(NCT04257656) COVID-19 were halted on April 15th for lack of patient
(‘’The epidemic of COVID-19 has been controlled well at present, no eligible
patients can be recruited’’), whilst Grein et al. [44] in April 10th pub-
lished on NEJM an interesting clinical improvement in 36 of 53 treated
patients (68%). In Italy, several studies involving RDV monotherapy in
patients with COVID19 infection of different severity are underway and
results are expected in the next two months. The opening of two Gilead
sponsored international registration studies is imminent and several
Asian and European centers will participate. For the Emilia Romagna
region the centers currently included in the study are: AOU of Parma
and the AUSL of Piacenza. The EC authorizations of AVEC are in pro-
gress. These consist in: 1) A Phase lll RCT in open-open in which 2
different RDV-based regimens (same dose, but different duration) will
be compared on a population of 400 patients suffering from COVI-19
pneumonia in severe form that at the time of entry into the study do not
require mechanical ventilation; 2) A phase lll open-label RCT in which
2 different RDV-based regimens (same dose, but different duration)
versus the standard of care in a population of 600 patients with mild
COVI19 pneumonia will be compared. Some SARS-CoV-2 patients have
received uncontrolled treatment with other investigational antivirals
[45].
Consequences of the hypothesis and discussion
The hypothesis to be tested is that local instillation of the study
products, i.e. RDV directly into the bronchial tree (via WHV) may be as
or more effective than systemic doses and reduce patients' exposure to
side effects, including increased liver enzymes, diarrhoea, rash, renal
failure and hypotension [44]. It should be noted that vaporisation
particles have a diameter greater than 8 µm impacting the oropharynx,
while aerosol particles, therefore capable of settling at the lower airway
level, are between 0,5 and 5 µm in size. So if the hypothesis is to attack
the virus in the oropharynx through the binding of SARS-COV-2 with
the ACE2 receptor also present in this district, vaporization would be
fine (both as suffumigation); but if we have to chase it into the lung, an
aerosol is mandatory. Local instillation, vaporization or aerosolization
of antivirals with WHV 40°–41 °C can significantly decrease viral re-
plication in hours or 2–3 days at most, in the early stages of respiratory
disease (preclinical and phenotype I Straw I [29], (Box 1). The amount
of product needed may be minimal, plausibly reducing disease evolu-
tion, patient pain and discomfort, drug consumption and social cost.
Vaporization with warmer air can also play a preventive role, and
we are considering it [10]
But… On March 23/2020, Gilead suspended access to Remdesivir®
for compassionate use (excepting cases of critically ill children and
pregnant women), for reasons related to supply, citing the need to
continue to provide agent for testing in clinical trials [46]. We sum-
marize here some warnings (Box 3).
The heat and alcohol / Pi susceptibility of SARS-CoV-2 may be a
vulnerable point of attack in the conjunctival or pharyngeal by rela-
tively simple means, especially in the context of a pandemic. Early
treatment with heated aerosol with antiviral drugs to avoid evolution
towards more severe pictures should take into account the advantages
of avoiding or improving the patient's severe clinical conditions leading
to muscular thoracic respiratory weakness, rhabdomyolysis, involved
pulmonary and cardiac microvasculature, hematological dyscrasia and
the long subsequent rehabilitation time required when leaving the
ICUs. In addition, the reduction of social costs, especially considering
that the proposed method can also be used by health systems with tight
budgets, especially in low-income countries, until global vaccination is
available.
Therefore, the first 2 weeks (incubation - preclinical phase) can be
an important window to avoid the progression towards the phases of
respiratory distress: it is therefore mandatory to avoid social contact
with known people at risk, and to enter quarantine in case of contact
with positive people, carefully following the rules. Suggested low level
auto prophylaxis (warm domestic aerosol, alcohol/pi gargles, eye drops
in case of conjunctivitis [32,51,52]) should be started as early as pos-
sible as it is free from the risk of side effects, leaving the prescription of
a second level active therapy to the physician and social doctors.
The cause of death among infected patients is the severe respiratory
insufficiency also linked to severe venous thromboembolism. Critical
patients with COVID often develop ARDS and require hospitalization in
intensive care, although oxygen therapy and assisted intubation do not
always save their lives because of the massive thrombosis that leads to
CID.
Further research is needed, including the monitoring of the endemic
stroke phase after the pandemic, the so-called Phase 2, mainly in de-
veloping countries, under WHO control.
Giovanni Belcaro MD, from the Darwin Lab & Irvine3 Labs and the
OOLEX C-virus project, Pescara, Italy, for the opportunity to discuss and
share the therapeutic approach.
Box 1
Paglia phenotypes classification.
Lecture by Dr Stefano Paglia, director of the Emergency
Department of Lodi, (‘red zone’), Italy, who in collaboration with
Chinese colleagues, has managed to identify SARS-CoV-2 positive
patients in 5 different phenotypes, which correspond to a possible
different therapeutic management [29]:
Phenotype I: patient with fever who does not necessarily
Fig. 3. Remdesivir®, G-S 5734, Gilead Science. A nucleic acid analogue, a sugar and one phosphate group. Image credit: PubChem.
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present respiratory symptoms, no hypoxia in arterial blood gas
analysis and chest x-ray negative. The swab is carried out only if
it is considered at risk of previous contact and is safely discharged
if, performing a specific respiratory activity test (6′ walking test
with an oximeter on the finger), he/she does not show any sig-
nificant alteration. At their “follow-up” no return to ER was ob-
served with a negative outcome. In these patients, ultrasound of
the chest is not recommended, because it will probably be posi-
tive and in any case will not indicate hospitalization. These are
believed to represent the majority of patients. Quarantine at
home and Practitioner control.
Phenotype II: patient with fever plus pulmonary thickening
on chest X-ray or in the presence of arterial blood gas hypoxia.
The patient must be hospitalized in the medical area and must be
observed: in the following hours he can either undergo rapid
deterioration or turn towards a significant improvement. The
patient cannot be discharged. These patients are approximately
20 times more frequent than those who end up in resuscitation.
Phenotype III: Hypoxia frank to arterial EGA, fever and
multiple thickenings to chest x-ray. The patient responds to
oxygen therapy set at 15 l / min (i.e. with SpO2 > 90 mmHg
with O2), and needs hospitalization in a sub-intensive area.
Phenotype IV: pre-respiratory distress syndrome picture that
requires C-PAP (continuous ventilation at positive pressure) to
obtain acceptable levels of oxygen pressure / flow ratio (normal
values above 350).
Phenotype V: full-blown respiratory distress syndrome, ty-
pical of males between 35 and 70 years of age arriving with
oxygen pressure values of up to 35–40 mmHg, apparently in less
serious conditions than the data show. Here pulmonary ultra-
sound can make the difference, distinguishing patients with “wet”
interstitial syndrome, i.e. only B lines and a sliding conserved, by
“dry” patients with an interstitial syndrome composed of multiple
pleural sub consolidations but reduced sliding. In the first case, an
attempt with C-PAP continuous ventilation at positive pressure is
desirable, while in the second, early intubation is mandatory.
Common feature of COVID19 positive patients is leukopenia,
associated with respiratory alkalosis on arterial blood gas ana-
lysis, with multiple lung consolidations on chest x-ray. CT is not
essential and is risky as it requires continuous transport of pa-
tients to other departments.
A common feature observed in the hospitals most involved, is
that there is a pre-epidemic phase of about a week with some
daily / sporadic cases followed by the real epidemic phase in




• 47D11 [23] (if confirmed), human antibody.
• EIDD-1931© / EIDD-2801© demonstrated in mouse and
human lung cells in vitro that viruses that show resistance to
Remdesivir® experience higher inhibition with the oral
compound and viceversa, suggesting that the two drugs
could be combined for greater efficacy and to prevent the
emergence of resistance [34], holding promise not only to
treat COVID-19, but also new coronaviruses that may
emerge in the future.
• APN01© is the recombinant form of the human angiotensin-
converting enzyme 2 (rhACE2), based on a dual mechanism
of action on pulmonary arterial hypertension (PAH), acute
lung injury (ALI), acute respiratory distress syndrome
(ARDS), and viral binding to soluble ACE2/APN01 avoiding
cell infection [35,36].
• Chloroquine derived drugs (approved off-label by AIFA).
• Colchicine (approved off-label by AIFA).
Box 3
Warning.
It’s important to observe that:
• Public health measures – the so-called non-pharmaceutical
interventions (NPIs) – aimed at reducing contact rates in the
population, and thereby reducing virus transmission, could
be oriented to: a) mitigation (focused on slowing but not
necessarily stopping epidemic spread); or b) suppression
(which aims to reverse epidemic growth, reducing case
numbers to low levels and maintaining that situation
indefinitely, until a vaccine becomes available) [47].
• Wearing personal protection devices, maintaining a high level
of personal/hands hygiene.
• Smoking is the most important cause of bronchospasm and
bronchial epithelial vasoconstriction. All smokers should be
advised to avoid smoking in this situation (unfortunately
this is an immediate subjective behaviour for cough and
dyspnoea in phenotype I, but to be evaluated in the pre-
clinical phase or of suspected or documented infection by
swab, even in asymptomatic patient).
• Vasoconstriction – as for cold – may significantly impair the
reaction to a virus; mostly in polluted environment.
• To use alcoholic/Pi gargle in pre-clinical subjective orophar-
yngeal symptoms could act as a protection against progres-
sion to tracheal-bronchial involvement.
• To use hot humid aerosol could improve pre-clinical subjec-
tive symptoms.
• Aerosol could act as a vector for local pharmaceutical supply.
• Ingestion of nebulized drug and probiotics can positively
interfere with intestinal-pulmonary cross-talk.
• At present, there is no drug approved for treating CoV-19 flu,
although trials are testing promising compounds; the only
therapeutic remedies are those aimed at the side effects
caused by the virus, such as inflammation, arterial blood gas
hypoxia, myocardial involvement [12,13] and ARDS till the
pulmonary fibrosis, up to now recognized as the first cause
of death [48], together with DIC.
• The anatomo-pathological finding of cardio-pulmonary micro-
vascular heavy pathology [12,13], causing death in 69,44%
between older patients with previous cardiovascular disease
(CVD) and increased troponin T (TnT), higher D‐dimer and
fibrin degradation product (FDP) levels, longer prothrombin
time and activated partial thromboplastin time in 71,4% of
non‐survivors in the overall mortality of 11.5%, met the Sofa
criteria of Disseminated Intravascular Coagulation (DIC)
[49]. That means that another cause of death must take in
account as viral consequence, mainly in phenotype IV-V,
that would impose to add to ventilation, antiviral and IL-
storm blocker, the proper anticoagulant therapies.
• Inhaling a mixture of gaseous hydrogen and oxygen, seems
obtaining better results than with oxygen alone. It was also
noted that individuals vaccinated for viral and/or bacterial
infectious diseases were less likely to become infected. The
germicidal UV radiation “breaks down” the oxygen O2 which
then aggregate into O3 molecules creating an ozone layer,
capable of inhibiting viral replication and improving lung
respiration. New anti-viral therapies with new drugs should
also be take into consideration. For example, microbes are
known to bind TLR, inducing IL-1, a pleiotropic cytokine,
highly inflammatory, mediator of fever and fibrosis.
Therefore, drugs that suppress IL-1 or IL-1R, also used for
the treatment of rheumatoid arthritis are to be taken into
consideration to fighting COVID-19 [48].
• Low-cost measures like nasal medicated hot vaporisation in
preclinical swab-positive asymptomatic patient or in
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phenotype I, and medicated aerosol in phenotypes II could
be suggested, complementary to systemic therapy.
• In hospitalized phenotypes III-V aerosol in oxygen breathing
mask with nucleotide analog or IL-6 blocker (acting on the
interrelationship between inflammatory cytokines [50])
could be add to systemic and resuscitation therapies.
• Looking for a vaccine, the actual target is to avoid the viral
adhesion to ACE2 pulmonary cells receptor where the pro-
inflammatory cascade. [48] induces the alveolar edema,
inhibit the O2/blood exchange and can evolve in interstitial
fibrosis, with microvascular and myocardial involvement.
The severity of the disease depends on the efficiency of the
immune system which, if weak, cannot stem the infection
and its symptoms. A strategy to enhance the anti-inflamma-
tory cytokines or suppress IL-1 or IL-1R, as suggested by
Conti et al. [11], would be effective.
• Blocking the IL-6 pro-inflammatory cascade with Tocilizumab®
via aerosol may also be tested, having clear in mind the
previous weak recommendation for α-interferon, as quoted
in text.
• Remdesivir® is a promising drug to act against CoV-1.
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